Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
ACHL | US
0.01
1.01%
Healthcare
Biotechnology
30/06/2024
18/10/2024
1.00
1.00
1.00
0.97
Achilles Therapeutics Plc a clinical stage immuno-oncology biopharmaceutical company develops precision T cell therapies to treat various solid tumors. The company's lead product candidates include CHIRON which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma. The company was formerly known as Achilles TX Limited and changed its name to Achilles Therapeutics Plc in February 2021. Achilles Therapeutics Plc was founded in 2016 and is headquartered in London the United Kingdom.
View LessPositive Momentum
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
Microcap (<300M USD)
High Market Beta (> 0.8)
Weak Sharpe Ratio (< 0.3)
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
10 days
26.8%1 month
119.4%3 months
74.7%6 months
61.5%-
-
0.35
0.04
0.03
1.66
-
-
-65.90M
42.20M
42.20M
-
-
-
-
-44.22
0.20
1.42
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
0.10
Range1M
0.39
Range3M
0.45
Rel. volume
0.02
Price X volume
44.05K
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Clene Nanomedicine Inc | CLNN | Biotechnology | 5.56 | 44.27M | 4.12% | n/a | -6472.02% |
LAVA Therapeutics BV | LVTX | Biotechnology | 1.68 | 44.18M | 1.82% | n/a | 14.37% |
CALC | CALC | Biotechnology | 4.08 | 43.86M | 3.04% | n/a | 0.00% |
Lexaria Bioscience Corp | LEXX | Biotechnology | 2.76 | 43.64M | -2.47% | n/a | 1.41% |
HOOKIPA Pharma Inc | HOOK | Biotechnology | 4.12 | 41.43M | -1.20% | n/a | 5.69% |
CARM | CARM | Biotechnology | 0.9748 | 40.50M | -2.50% | n/a | 1044.17% |
Equillium Inc | EQ | Biotechnology | 1.13 | 40.03M | 4.63% | n/a | 2.71% |
Common Stock | TARA | Biotechnology | 1.91 | 39.40M | 3.24% | n/a | 5.41% |
FibroGen Inc | FGEN | Biotechnology | 0.3915 | 39.31M | -0.89% | n/a | -70.49% |
NextCure Inc | NXTC | Biotechnology | 1.37 | 38.33M | -5.52% | n/a | 7.21% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Beasley Broadcast Group Inc | BBGI | Broadcasting - Radio | 12.9 | 19.65M | 2.38% | n/a | 204.46% |
ILAG | ILAG | Building Products & Equipment | 1.03 | 18.60M | 5.10% | n/a | 5.48% |
Antelope Enterprise Holdings Limited | AEHL | Building Products & Equipment | 0.538 | 7.80M | -6.65% | 0.03 | 16.03% |
Forza X1 Inc | FRZA | Recreational Vehicles | 0.2201 | 3.95M | 4.26% | n/a | 0.97% |
EZGO Technologies Ltd. Ordinary Shares | EZGO | Recreational Vehicles | 1.06 | 2.76M | 1.92% | n/a | 17.32% |
Micromobility.com Inc. | MCOM | Recreational Vehicles | 0.01 | 897.66K | -12.28% | n/a | -37.05% |
Winnebago Industries Inc | WGO | Recreational Vehicles | 60.38 | 0 | 0.37% | 22.53 | 56.33% |
Vision Marine Technologies Inc | VMAR | Recreational Vehicles | 3.92 | 0 | -8.84% | n/a | 0.00% |
Twin Vee PowerCats Co. Common Stock | VEEE | Recreational Vehicles | 0.4801 | 0 | -10.26% | n/a | 19.98% |
Urban One Inc | UONEK | Broadcasting - Radio | 1.045 | 0 | -2.34% | n/a | 268.43% |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | 1.66 | 0.53 | Expensive |
Ent. to Revenue | - | 3,967.00 | - |
PE Ratio | - | 41.03 | - |
Price to Book | 0.35 | 15.55 | Cheaper |
Dividend Yield | - | 2.20 | - |
Std. Deviation (3M) | 74.72 | 72.80 | Par |
Debt to Equity | 0.04 | -1.23 | Expensive |
Debt to Assets | 0.03 | 0.25 | Cheaper |
Market Cap | 42.20M | 3.66B | Emerging |